Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Nomura: BEIGENE (06160.HK) Hikes No. of Preclinical Studies to 85 This Yr, Conducting 96 Clinical Trials
Recommend 6 Positive 7 Negative 0 |
||||
|
||||
|
BEIGENE (06160.HK) held an R&D day in New York on Thursday (26th), where management emphasized the Company's R&D capabilities in terms of quality, speed and cost, Nomura published a research report saying. The Company has increased the number of preclinical studies from 20 in 2019 to 85 this year, while new molecules entering the clinical stage reached 10 in 2024. The Company is currently conducting 96 clinical trials, with more than half involving solid tumors. Therefore, the broker rated BEIGENE at Buy, with a target price of $206.6. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
